The American Academy of Pediatrics believes the time has come for the federal government to reclassify marijuana in order to facilitate research. In a recent policy statement, the national committee on substance abuse said that while they do not support medical marijuana outside the regulatory confines of the United States Food and Drug Administration, they do recommend the government downgrade the Schedule I classification of the herb, so that science can begin to properly explore its health potential.
Although the health society is adamant that it does not support the concept of medical marijuana as 23 states and the District of Columbia have come to understand it, they are recommending the Drug Enforcement Administration downgrade the classification of cannabis to a Schedule II controlled substance because they realize “cannabinoid administration” may be the only effective recourse for children suffering from debilitating or life-threatening conditions.
“A Schedule 1 listing means there’s no medical use or helpful indications, but we know that’s not true because there has been limited evidence showing [marijuana] may be helpful for certain conditions in adults,” Dr. Seth Ammerman, a co-author of the study, told The Wall Street Journal.
“By placing this on Schedule 2, it would allow the FDA to be involved [in pediatric research] as the agency is in any study,” he continued. “Unless scheduling changes, this won’t happen. And there could be therapeutic benefits. The AAP is not opposed to medical marijuana, per se, but we feel it’s important that this be explored within the [framework of the] FDA process, where you have standardization.”
Perhaps the most common disease discussed in relation to children and marijuana is Epilepsy. In early 2014, the Epilepsy Foundation released a similar statement calling for the DEA to reconsider the Schedule I classification of marijuana in order to promote research. Yet, even though more states have legalized the herb for the sole purpose of treating epileptic children, the Obama Administration has done nothing to initiate any level of reform to the Controlled Substances Act.
In the meantime, the federal government has allowed GW Pharmaceuticals to conduct clinical trials in the United States with their cannabis-based epilepsy drug Epidiolex, bringing attention to corporate corruption that stands in the way of a nationwide medical marijuana program. Once the FDA puts its final stamp of approval on this medicine, which is expected, the DEA will simply classify it a Schedule II or III substance in order to bring it to market.
The AAP statement also recommends that marijuana be decriminalized across the nation, and “encourages pediatricians to advocate for laws that prevent harsh criminal penalties for possession or use of marijuana.”
Mike Adams writes for stoners and smut enthusiasts in HIGH TIMES, Playboy’s The Smoking Jacket and Hustler Magazine. You can follow him on Twitter @adamssoup and on Facebook/mikeadams73.
(Photo via huffingtonpost.com)
Cody Alt Builds CBD Company in 7 Months, Now Launching Cannabis Products
Lawmakers Want To Charge Doctors Who Prescribe Cannabis With A Felony
7 Scientists Who Smoked Weed
Moms Who Get High
Recreational Marijuana in Canada Will Be Delayed
10 Best Vape Pens of 2017 for Cannabis Concentrates
10 Best Dab Rigs Of 2017
How To Grow Organic Weed: A Step-by-Step Guide
6 Sickest Space Bucket Designs
11 Markets That Benefit From Weed Legalization
Products4 days ago
10 Best Portable Vaporizers of 2017
Guides1 week ago
6 Ways To Get Better Bong Rips
Products2 days ago
10 Best Quartz Bangers Of 2017
Entertainment3 days ago
Nine Authors Who Smoked Weed
Culture2 days ago
The Origins of Your Favorite Weed Slang
Health1 week ago
How To Treat Endometriosis With Cannabis
Dispensaries1 week ago
First Medical Marijuana Dispensary In Texas Open For Business
News1 week ago
How Much Are Canadians Paying For Marijuana?